According to the study, ‘CARDIAC VALVE REPAIRS-MEDICAL DEVICES PIPELINE ASSESSMENT, 2018’, for many, valve tightness can be relieved during a procedure called balloon valvuloplasty which is done as part of a cardiac catheterization which is less invasive than general surgery or open heart surgery. Commissurotomy is used for narrowed valves, where the leaflets are thickened and sometimes stuck together. The surgeon opens the valve by cutting the points where the leaflets meet. New progress in medical science has been improving the scenario considerably, evident by developments in treatment of ailments such as mitral regurgitation.
Today, there is an immediate concern regarding heart diseases which are on the rise owing to lifestyle imbalances. There are several heart valve ailments, all of which reduce the efficiency of the heart by reducing functionality of the valves. Options are available today that can resolve valve ailments either by repair or by replacement. When possible it is generally best to repair a valve and preserve a person’s own tissue in the heart. However, if the tissue is too damaged, a replacement valve may be used from another human heart, an animal or a manufactured mechanical valve.
Mitral regurgitation is the most common valvular disease and significant severity levels of mitral regurgitation are found in a few people above the age of 65 years. There are several features of the mitral valve for instance, its saddle-shaped non calcified annulus and irregular leaflet geometry, that make a transcatheter approach to repair or replace the valve more challenging compared to the aortic valve. New transcatheter minimally invasive technologies are being developed to address mitral valve disease in patients deemed too high a risk for conventional open-heart surgery. Several devices are under investigation for mitral valve repair, targeting the mitral valve leaflets, chordae tendinae and mitral annulus. The MitraClip device is the only Food and Drug Administration (FDA) approved device to treat mitral regurgitation by targeting the mitral leaflets. Currently there are more than ten different transcatheter mitral valves that are in various stages of development and clinical trials. These transcatheter mitral valves can be delivered either through a transseptal, transapical, transaortic, or left atriotomy approach.
Many big medical companies are exploring the prospects of cardiac valve treatment. US based Abbott Laboratories is a healthcare company that has recently been part of major developments in mitral valve treatment. In May 2018, Abbott announced favorable outcomes from the first hundred patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement System (TMVR) system, the first and only mitral replacement valve that is repositionable and fully retrievable to allow for more precise implantation to improve patient outcome. This trial is the largest study of a transcatheter mitral valve replacement device to date.
Cardiac valve treatment is proving to be a flourishing research sector with more and more developments taking place. Repairing cardiac valves is increasingly incorporating new research evident by the developments in treatment of mitral regurgitation. New devices are being developed and certified by reliable establishments such as the US based FDA and many more are in the making. Global giants like Abbott are also showing their interests in heart valve treatment evident by their recent research project on transcatheter mitral valve replacement.
To know more, click on the link below:
Ankur Gupta, Head Marketing & Communications